Orchard Therapeutics has secured reimbursement from another European market for Libmeldy, an ex vivo gene therapy for the rare childhood disease metachromatic leukodystrophy (MLD) first approved in the EU in 2020. The Spanish agreement follows similar reimbursement agreements in the UK, Germany, Italy, and other European countries and, as a result, Orchard is working to qualify its seventh European treatment centre for Libmeldy in Spain. Source: Pharmaphorum 28/2/25